Lista de obras -

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

scientific article published on 05 August 2019

A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor-α (TNF-α) inhibitor, adalimumab

artículo científico publicado en 2020

A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease

artículo científico publicado en 2020

A review of upadacitinib in rheumatoid arthritis

artículo científico publicado en 2020

Anifrolumab, a Monoclonal Antibody to the Type I Interferon Receptor Subunit 1, for the Treatment of Systemic Lupus Erythematosus: An Overview From Clinical Trials

artículo científico publicado en 2020

COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration

scientific article published on 25 August 2020

Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR

artículo científico publicado en 2020

Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus

artículo científico publicado en 2020

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease

scientific article published on 22 June 2019

Development of the Asia Pacific Lupus Collaboration cohort

article

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

artículo científico publicado en 2020

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 study

artículo científico publicado en 2020

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

scientific article published on 26 July 2019

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

scientific article published on 26 July 2019

Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases

artículo científico publicado en 2020

Epstein–Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor

artículo científico publicado en 2022

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

artículo científico publicado en 2020

Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Wa

artículo científico publicado en 2019

First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort

scientific article published on 06 November 2019

IL-2 drives conversion of T follicular helper cells to T follicular regulatory cells through transcriptional regulation in systemic lupus erythematosus

artículo científico publicado en 2020

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction

scientific article published on 01 July 2020

Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis

artículo científico publicado en 2020

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

artículo científico publicado en 2020

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

artículo científico publicado en 2019

Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials

scientific article published on 29 April 2020

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

artículo científico publicado en 2020

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

artículo científico publicado en 2020

Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al

scientific article published on 09 December 2019

Rheumatoid arthritis

scientific article published on 07 September 2020

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

scientific article published on 28 October 2020

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

scientific article published on 20 March 2019

Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports

artículo científico publicado en 2020

State-of-the-art treatment of systemic lupus erythematosus

artículo científico publicado en 2020

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

scientific article published on 19 October 2019

Systemic Lupus Erythematosus: Targeted literature review of the epidemiology, current treatment and disease burden in the Asia Pacific region

scientific article published on 25 August 2020

The approach to precision medicine for the treatment of psoriatic arthritis

scientific article published on 20 April 2020

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

scientific article published on 05 July 2019

Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages

scientific article published on 12 February 2020

Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators

artículo científico publicado en 2020

Lista de obras de

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

A case of bone destruction caused by chronic non-bacterial osteomyelitis (CNO) successfully repaired with a tumour necrosis factor-α (TNF-α) inhibitor, adalimumab

A case of eosinophilic granulomatosis with polyangiitis as a mimicker of IgG4-related disease

A review of upadacitinib in rheumatoid arthritis

Anifrolumab, a Monoclonal Antibody to the Type I Interferon Receptor Subunit 1, for the Treatment of Systemic Lupus Erythematosus: An Overview From Clinical Trials

COVID-19 infection in patients with systemic lupus erythematosus: Data from the Asia Pacific Lupus Collaboration

Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR

Changes in endothelial function during educational hospitalization and the contributor to improvement of endothelial function in type 2 diabetes mellitus

Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease

Development of the Asia Pacific Lupus Collaboration cohort

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 study

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases

Epstein–Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation

Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Wa

First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort

IL-2 drives conversion of T follicular helper cells to T follicular regulatory cells through transcriptional regulation in systemic lupus erythematosus

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction

Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials

Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al

Rheumatoid arthritis

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Short-term effectiveness of ixekizumab to refractory psoriatic arthritis with spondyloarthritis: two case reports

State-of-the-art treatment of systemic lupus erythematosus

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

Systemic Lupus Erythematosus: Targeted literature review of the epidemiology, current treatment and disease burden in the Asia Pacific region

The approach to precision medicine for the treatment of psoriatic arthritis

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis

Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages

Two patients with mixed connective tissue disease complicated by pulmonary arterial hypertension showing contrasting responses to pulmonary vasodilators